Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor

被引:69
作者
Hara, S [1 ]
Oya, M [1 ]
Mizuno, R [1 ]
Horiguchi, A [1 ]
Marumo, K [1 ]
Murai, M [1 ]
机构
[1] Keio Univ, Sch Med, Dept Urol, Shinjuku Ku, Tokyo 1608582, Japan
关键词
Akt; Bad; PTEN; renal cell carcinoma;
D O I
10.1093/annonc/mdi182
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Akt has been implicated in the oncogenesis of human malignant tumors, because Akt regulates many key effector molecules involved in cell survival. PTEN (phosphatase and tensin homolog deleted on chromosome 10) negatively regulates Akt activation. Materials and methods: The expression of phosphorylated Akt (p-Akt), total Akt and PTEN was analyzed by Western blotting in 45 renal cell carcinoma (RCC) patients. The Bad and phosphorylated Bad (p-Bad) statuses were analyzed in 20 RCC patients. A phosphatidylinositol ether analog was used as an Akt inhibitor to treat four RCC cell lines, namely Caki-1, KU19-20, SW839 and Caki-2. Results: The PTEN expression in RCC was observed to decrease and p-Akt expression to increase significantly in comparison with that in the corresponding normal kidney tissue. The PTEN expression inversely correlated with the p-Akt expression. These alterations were specific for clear cell type RCC, but not for papillary or chromophobe type RCC. Alterations in Bad phosphorylation were also specifically observed in clear cell type. The Akt inhibitor induced apoptosis in KU19-20 and Caki-2 cells with a high Akt activity. Conclusions: A decreased expression of PTEN may be an underlying mechanism for Akt activation. An Akt inhibitor may be a therapeutic option for a subset of RCC with an elevated Akt activity.
引用
收藏
页码:928 / 933
页数:6
相关论文
共 19 条
[1]  
Alimov A, 1999, ANTICANCER RES, V19, P3841
[2]   Loss of tumor suppressor protein PTEN during renal carcinogenesis [J].
Brenner, W ;
Färber, G ;
Herget, T ;
Lehr, HA ;
Hengstler, JG ;
Thüroff, JW .
INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (01) :53-57
[3]   Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers [J].
Cairns, P ;
Evron, E ;
Okami, K ;
Halachmi, N ;
Esteller, M ;
Herman, JG ;
Bose, S ;
Wang, SI ;
Parsons, R ;
Sidransky, D .
ONCOGENE, 1998, 16 (24) :3215-3218
[4]   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery [J].
Datta, SR ;
Dudek, H ;
Tao, X ;
Masters, S ;
Fu, HA ;
Gotoh, Y ;
Greenberg, ME .
CELL, 1997, 91 (02) :231-241
[5]   Renal cell carcinoma: Management of advanced disease [J].
Figlin, RA .
JOURNAL OF UROLOGY, 1999, 161 (02) :381-386
[6]   PI3K: Downstream AKTion blocks apoptosis [J].
Franke, TF ;
Kaplan, DR ;
Cantley, LC .
CELL, 1997, 88 (04) :435-437
[7]   Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma [J].
Horiguchi, A ;
Oya, M ;
Uchida, A ;
Marumo, K ;
Murai, M .
JOURNAL OF UROLOGY, 2003, 169 (02) :710-713
[8]   3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth [J].
Hu, YH ;
Qiao, LX ;
Wang, SM ;
Rong, SB ;
Meuillet, EJ ;
Berggren, M ;
Gallegos, A ;
Powis, G ;
Kozikowski, AP .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (16) :3045-3051
[9]   Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma [J].
Itoh, N ;
Semba, S ;
Ito, M ;
Takeda, H ;
Kawata, S ;
Yamakawa, M .
CANCER, 2002, 94 (12) :3127-3134
[10]  
Kanamori Y, 2001, CLIN CANCER RES, V7, P892